Acadian Asset Management LLC Infinity Pharmaceuticals, Inc. Transaction History

Acadian Asset Management LLC

$32.2 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$2.66 - $3.47 $1.95 Million - $2.54 Million	-732,669 Closed	0 $0
Q1 2021 May 11, 2021	SELL	$1.98 - $5.36 $122,595 - $331,875	-61,917 Reduced 7.79%	732,669 $2.37 Million
Q4 2020 Feb 11, 2021	BUY	$1.05 - $2.77 $154,551 - $407,721	147,192 Added 22.74%	794,586 $1.68 Million
Q3 2020 Nov 09, 2020	BUY	$0.82 - $1.34 $42,215 - $68,985	51,482 Added 8.64%	647,394 $758,000
Q2 2020 Aug 12, 2020	BUY	$0.77 - $1.13 $5,419 - $7,952	7,038 Added 1.2%	595,912 $539,000
Q1 2020 May 11, 2020	SELL	$0.69 - $1.52 $30,867 - $67,998	-44,736 Reduced 7.06%	588,874 $493,000
Q4 2019 Feb 06, 2020	BUY	$0.88 - $1.29 $11,233 - $16,466	12,765 Added 2.06%	633,610 $609,000
Q3 2019 Nov 07, 2019	BUY	$1.03 - $1.75 $19,907 - $33,824	19,328 Added 3.21%	620,845 $640,000
Q2 2019 Aug 08, 2019	BUY	$1.43 - $1.87 $84,367 - $110,326	58,998 Added 10.87%	601,517 $1.08 Million
Q1 2019 May 09, 2019	BUY	$1.18 - $1.91 $71,251 - $115,331	60,383 Added 12.52%	542,519 $1.02 Million
Q4 2018 Feb 07, 2019	BUY	$1.01 - $2.78 $128,946 - $354,922	127,670 Added 36.02%	482,136 $569,000
Q3 2018 Oct 30, 2018	SELL	$1.72 - $2.71 $30,173 - $47,541	-17,543 Reduced 4.72%	354,466 $961,000
Q2 2018 Jul 24, 2018	BUY	$1.72 - $2.26 $312,069 - $410,045	181,436 Added 95.21%	372,009 $711,000
Q1 2018 Apr 12, 2018	BUY	$1.8 - $2.74 $284,412 - $432,939	158,007 Added 485.19%	190,573 $400,000
Q4 2017 Jan 18, 2018	SELL	$1.22 - $3.73 $5,389 - $16,479	-4,418 Reduced 11.95%	32,566 $66,000
Q3 2017 Oct 13, 2017	BUY	$0.94 - $1.35 $34,764 - $49,928	36,984	36,984 $49,000

Others Institutions Holding INFI

# of Institutions

Shares Held

1.26M

Call Options Held

Put Options Held

View Full List

About INFINITY PHARMACEUTICALS, INC.

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

More about INFI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Account